Form 8-K - Current report:
SEC Accession No. 0001835268-25-000044
Filing Date
2025-07-21
Accepted
2025-07-21 09:05:32
Documents
12
Period of Report
2025-07-18
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntb-20250718.htm   iXBRL 8-K 30695
  Complete submission text file 0001835268-25-000044.txt   151442

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntb-20250718.xsd EX-101.SCH 1806
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntb-20250718_lab.xml EX-101.LAB 22498
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntb-20250718_pre.xml EX-101.PRE 13245
15 EXTRACTED XBRL INSTANCE DOCUMENT cntb-20250718_htm.xml XML 2891
Mailing Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130
Business Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130 858-727-1040
Connect Biopharma Holdings Ltd (Filer) CIK: 0001835268 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40212 | Film No.: 251135902
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)